Drug Trial Radar · NCT06964776
A Study of LY4268989 (MORF-057) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
May 1, 2025
Primary completion
Feb 17, 2026
Study completion Feb 17, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Conditions
- Healthy
Interventions
LY4268989Drug
Administered orally
PlaceboDrug
Administered placebo
MidazolamDrug
Administered orally
MidazolamDrug
Administered intravenously (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4268989 (Cohort 1) and (Cohort 5)Time frame: Day 1 to Day 17
- PK: Area Under the Concentration Curve (AUC) of LY4268989 (Cohort 1) and (Cohort 5)Time frame: Day 1 to Day 17
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Cohort 1), (Cohort 3), and (Cohort 5)Time frame: Baseline to Study Completion (Up to Day 17)
- Number of Participants with TEAEs and SAEs (Cohort 4)Time frame: Baseline to Study Completion (Up to Period 4, Day 4)
- PK: Cmax of LY4268989 (Cohort 2)Time frame: Day 1 to Day 13
- PK: AUC of LY4268989 (Cohort 2)Time frame: Day 1 to Day 13
- PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 3)Time frame: Day 1 to Day 17
- PK: AUC of Midazolam and 1'-Hydroxymidazolam (Cohort 8)Time frame: Day 3 and Day 11
- PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 3)Time frame: Day 1 to Day 17
- PK: Cmax of Midazolam and 1'-Hydroxymidazolam (Cohort 8)Time frame: Day 3 to Day 11
- PK: Cmax of LY4268989 (Cohort 6)Time frame: Day 1 to Day 7
- PK: AUC of LY4268989 (Cohort 6)Time frame: Day 1 to Day 7
- PK: Cmax of LY4268989 (Cohort 7)Time frame: Day 1 to Day 12
- PK: AUC of LY4268989 (Cohort 7)Time frame: Day 1 to Day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExel ACT
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.